Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Kevin Pfleger?

Kevin Pfleger

Chief Scientific Officer

Dimerix Limited

HQ Phone:  +61 8 9481 3860

Email: k***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Dimerix Limited

Level 2 1 Walker Avenue

Perth, Western Australia,6005

Australia

Company Description

Dimerix's lead therapy, known as DMX200, is targeted at treating patients with chronic kidney disease. The initial focus is to provide a treatment for persistant proteinuria (abnormally high levels of protein in the urine) caused by chronic kidney disease. The... more.

Find other employees at this company (10)

Background Information

Employment History

Head, Molecular Endocrinology and Pharmacology

Harry Perkins Institute of Medical Research


Affiliations

The University of Western Australia

Associate Professor - NHMRC RD Wright Biomedical Research Fellow (Level 2)


National Health and Medical Research Council

RD Wright Biomedical Research Fellow and Head


University of Western Ontario

Australian Research Council Future Fellow and Research Associate Professor


Australian Research Council

Future Fellow and Head of Molecular Endocrinology and Pharmacology


Australian Research Council

Future Fellow


National Health and Medical Research Council

Peter Doherty Research Fellow


NHMRC Peter Doherty Research Fellow and Australian Research Council

Future Fellow


Education

BA


MA

Cambridge


MA

Edinburgh University


Ph.D.

Harry Perkins Institute of Medical Research


Ph.D.

University of Western Australia , Australia


PhD

Cambridge University


PhD

Edinburgh Universities


bachelors/masters degrees

Cambridge University


Web References(110 Total References)


Management Team – Dimerix Limited

dimerix.com [cached]

Kevin Pfleger, Dimerix
Kevin Pfleger Kevin Pfleger Kevin Pfleger, Dimerix Kevin Pfleger BA (Hons), MA, PhD Chief Scientific Adviser Associate Professor Kevin Pfleger is a National Health and Medical Research Council (NHMRC) RD Wright Biomedical Research Fellow (Level 2) and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research (formerly Western Australian Institute for Medical Research, WAIMR) and The University of Western Australia. Kevin was Chief Scientific Officer of Dimerix Bioscience from 2008 until Dimerix became a public company in June 2014. He was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively. Kevin is one of the world's foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G protein-coupled receptors. He has published the seminal review and protocol for BRET in Nature Methods and Nature Protocols respectively, and is co-inventor of the HIT technology assigned to Dimerix from The University of Western Australia.


dimerix.com

Kevin Pfleger
Kevin Pfleger BA (Hons), MA, PhD Chief Scientific Officer Associate Professor Kevin Pfleger is an Australian Research Council (ARC) Future Fellow and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research (formerly Western Australian Institute for Medical Research, WAIMR) and The University of Western Australia. He was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively. Kevin is one of the world's foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G protein-coupled receptors. He has published the seminal review and protocol for BRET in Nature Methods and Nature Protocols respectively, and is co-inventor of the HIT technology assigned to Dimerix from The University of Western Australia.


www.sciencewa.net.au

Associate Professor Kevin Pfleger.
Associate Professor Kevin Pfleger. Image credit: Perkins' Institute Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research, Associate Professor Kevin Pfleger, is also Chief Scientific Advisor of biotechnology company Dimerix that is on track to release early results in the coming months from Phase II clinical trials of its flagship drug therapy DMX-200. A/Prof Pfleger says these blocker compounds were selected due to finding a functional interaction between the receptors they bind to in human kidney cells. "These findings have been published in the scientific journal PLoS One, validated in rodent models by colleagues at St.Vincent's in Melbourne, and have led to the Phase II clinical trials" A/Prof Pfleger says. A/Prof Pfleger says that this therapy also has the potential to treat other conditions and Dimerix is now investigating it for the treatment of non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease. NASH is a severe disease affecting an estimated 6 million people in the US alone that currently has no established treatment. A/Prof Pfleger, who is Chair-Elect of the Scientific Advisory Committee of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), has recently been awarded the prestigious Novartis Prize of the British Pharmacological Society and will receive this prize in December in London.


Management

dimerix.com [cached]

Kevin Pfleger BA (Hons), MA, PhD
Chief Scientific Officer A/Prof Kevin Pfleger is the Chief Investigator of the Dimerix-funded research program being carried out in the Laboratory for Molecular Endocrinology under agreement with WAIMR and the University of Western Australia. Kevin is one of the world's foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G-protein coupled receptors. He has published the seminal review and protocol for BRET in Nature Methods and Nature Protocols respectively, as well as publishing a novel derivation of the BRET technology, termed eBRET, that now enables prolonged monitoring of protein-protein interactions in real-time over timescales not previously possible. Kevin is co-inventor of the GPCR-HIT technology assigned to Dimerix from the University of Western Australia. Kevin Pfleger, Awarded the 2011 3M Eureka Prize for Emerging Leader in Science


Dimerix - Dimerix Team

www.dimerix.com [cached]

Kevin Pfleger
Kevin Pfleger BA (Hons), MA, PhD Chief Scientific Officer A/Prof Kevin Pfleger is the Chief Investigator of the Dimerix-funded research program being carried out in the Laboratory for Molecular Endocrinology under agreement with WAIMR and the University of Western Australia. Kevin is one of the world's foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G-protein coupled receptors. He has published the seminal review and protocol for BRET in Nature Methods and Nature Protocols respectively, as well as publishing a novel derivation of the BRET technology, termed eBRET, that now enables prolonged monitoring of protein-protein interactions in real-time over timescales not previously possible. Kevin is co-inventor of the GPCR-HIT technology assigned to Dimerix from the University of Western Australia.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory